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study was to perform a cost-effectiveness analysis of ﬁrst-line
monotherapy medications for the treatment of glaucoma.
METHODS: This study was a cost-effectiveness analysis of
latanoprost, brimonidine and beta-blockers for treatment of
glaucoma. Data for the study came from a VA medical center.
Patients were eligible if they had a prescription for latanoprost,
brimonidine or beta-blockers as monotherapy for glaucoma. The
outcomes of interest were change and percent change in intraoc-
ular pressure (IOP). The perspective of the analysis was from that
of a VA medical center and included direct medical costs.
RESULTS: A total of 318 eyes were evaluated, 78 receiving 
beta blockers, 34 receiving brimonidine, and 206 receiving
latanoprost. The majority of patients were white males and the
mean age was 73 years. Patients receiving latanoprost had a
mean(SD) IOP reduction of 7.59(4.6)mmHg compared to
6.8(5.0)mmHg for beta-blockers (p = 0.18), and there was no
signiﬁcant difference was observed between the mean for bri-
monidine (7.1(4.7)mmHg) and beta-blockers (p = 0.76). The
mean percent change in IOP was identical for latanoprost and
brimonidine (29.6%), but only 24.8% for those receiving beta-
blockers. Average (SD) daily cost was $0.05(0.09) for beta-
blockers, $0.29(0.39) for brimonidine, and $0.30(0.42) for
latanoprost (p < 0.001). However, the most cost-effective agent
was brimonidine, with a daily cost of $7.15 for each percent
reduction in IOP. Latanoprost demonstrated a daily cost per
percent IOP reduction of US$7.58. Both brimonidine and
latanoprost were more cost-effective than the beta-blockers with
a cost-effectiveness ratio of US$8.42. The incremental cost-
effectiveness of using brimonidine or latanoprost compared to
beta-blockers was $3.23 and $5.05, respectively. CONCLU-
SIONS: The results suggest that despite a much lower cost, beta-
blockers are not more cost-effective than brimonidine or
latanoprost.
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OBJECTIVE: To determine the economic resources utilized in a
cohort of patients with age-related macular degeneration.
METHODS: An Institutional Review Board-approved, resource
utilization study determined the economic resources used by a
cohort of AMD patients over a historical 12-month period from
the societal perspective. We evaluated costs by administering an
interviewer-administered questionnaire and reviewing partici-
pants’ clinic charts. From these two data sources, we evaluated
both direct medical costs and direct non-medical costs (such as
home support and assessment and low vision rehabilitation
including CCTV magniﬁers). Indirect costs incurred by family
members related to medical visits and supportive care were eval-
uated; productivity was not evaluated due to the low employ-
ment rate in this demographic. Statistical analyses included
determining the mean and variance about the main cost drivers.
In addition, a series of multivariate models evaluated if visual
dysfunction and other clinical variables were associated with
economic resources utilized. RESULTS: The 41 subjects included
in this analysis had a mean age of 79.6 years (SD 6.1); 64% were
females. Seventy-four percent of the sample had wet AMD, and
38.4% of the sample had bilateral wet disease. The median dura-
tion of disease was 16.9 months. The mean logMAR visual
acuity of the sample was 0.51 in the better seeing eye (20/65)
and 1.17 in the worse seeing eye (20/300). The mean annual cost
per patient in this sample was $3944.62 (CND). Direct medical
costs were the main cost driver, accounting for 91% ($3605) of
total costs. Multivariate linear regression using stepwise variable
selection demonstrated that both duration (p = 0.02) and visual
acuity in the better-seeing eye (p = 0.05) were signiﬁcantly asso-
ciated with increasing consumption of direct non-medical
resources. CONCLUSIONS: The economic resources utilized by
AMD patients are high, and visual acuity in the better-seeing eye
is inversely related to direct non-medical costs.
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OBJECTIVES: To investigate whether ethnicity was associated
with differences in Medicaid eligibility, health care utilization,
and direct medical costs over time in a systemic lupus erythe-
matosus (SLE) population. METHODS: A retrospective analysis
of California Medicaid claims data was conducted on patients
with a diagnosis of SLE. The patient monitoring period spans a
7-year (84 month) timeframe. Patient eligibility and month-by-
month utilization and costs were computed and compared across
ethnic groups. Descriptive statistics are presented with ﬁgures or
tables detailing activity during the monitoring period. A mixed
regression model on patient-level data was used to verify the
trends of the aggregate data, controlling for covariates.
RESULTS: Hispanic patients have shorter eligibility compared to
other cohorts (about 50% vs. 70% remain eligible at Month 36,
respectively). Over time, Hispanics generated lower total costs
than other cohorts. Results for inpatient frequency, prescription
costs and outpatient/physician/supply costs followed similar pat-
terns. Mixed regression model ﬁndings revealed that when
adjusted for age, gender and aid program, total costs for His-
panic patients decreased as the length of care increased, in con-
trast to the experience of other ethnic groups. The interaction
between ethnicity and treatment progression measured by
quarter was signiﬁcant (p < 0.0001), but ethnicity as a main
effect was not (p = 0.091). Differences in total costs appear small
initially, but as the follow-up period gets longer, Hispanic
patients experience lower total costs. CONCLUSIONS: These
preliminary longitudinal data in a single state Medicaid program
may imply that Hispanics with lupus either have slower disease
progression than other ethnic groups, are able to return to work
faster, or have difﬁculties with access to care.
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OBJECTIVES: Methyl aminolevulinate cream is the ﬁrst licensed
topical PDT product in the UK to treat actinic keratoses (AK).
It is activated when the cream is illuminated with a red light
source (MAL-PDT). In the UK, the incidence rate of AK is 5%.
The aim of this study was to assess the cost-effectiveness of
MAL-PDT versus the most commonly used intervention,
cryotherapy. METHODS: Clinical outcomes were obtained from
a multicentre comparative trial of difﬁcult to treat AK (Foley et
al. Journal of Dermatol Treat (2003)), deﬁned as thin or non-
hyperkeratotic AK on the face or scalp. Resource use was from
a Delphi panel of dermatologists and costs from standard UK
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sources. The NHS perspective was taken and included direct
costs only. In the decision analytical model, patients either
receive MAL-PDT or cryotherapy ﬁrst line with second line
therapy depending on lesion response. A one-year time horizon
was used to capture all relevant resource use and to assess the
clinical response. An excellent cosmetic outcome was deﬁned as
100% complete lesion response, but also no scarring, atrophy or
induration, and no or slight occurrence of redness or change in
pigmentation compared to adjacent skin. Key efﬁcacy data from
the clinical trial were subjected to a stochastic sensitivity analy-
sis using a Beta prior distribution and 1000 simulations.
RESULTS: From the deterministic model, the MAL-PDT strat-
egy dominated cryotherapy. Seventy-three percent of patients
had an excellent cosmetic outcome with MAL-PDT at a cost of
£832.93 per patient compared to 42% of cryotherapy patients
(£843.08 per patient). In the stochastic analysis using 1000 sim-
ulations, 95% of the ICERs were in the range -£161 to £191.
MAL-PDT was the dominant in strategy in 66.3% of the simu-
lations. CONCLUSIONS: MAL-PDT is at least as cost-effective
as cryotherapy in the treatment of thin or non-hyperkeratotic
actinic keratoses (AK) on the face or scalp and has superior cos-
metic outcomes.
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OBJECTIVE: To compare the annual costs of treatment incurred
by a health plan for patients diagnosed with actinic keratosis
(AK) and treated with ﬂuorouracil or cryosurgery. METHODS:
Pharmacy and medical claims from 2.7 million members of a
managed care organization in California, Oklahoma, Oregon,
Texas, and Washington, were examined. Adult patients newly
treated for AK with either 5% ﬂuorouracil cream or cryosurgery,
between January 1 and December 31, 2001, were identiﬁed.
Patients treated with cryosurgery were further stratiﬁed by
number of lesions (i.e., 1, 2–14, >15). Disease-related health care
costs (pharmacy and medical) for a 2-year follow-up period were
evaluated. RESULTS: Of the 9279 identiﬁed patients, 498
(5.4%) were treated with ﬂuorouracil and dermatologists pre-
scribed this medication (48.4%) more often than other special-
ties. Among the 8781 patients treated with cryosurgery, 3004
(34.2%), 5130 (58.4%), and 647 (7.4%) were identiﬁed with 1,
2–14, and >15 lesions, respectively. Total disease-related health
care costs during the follow-up period for the ﬂuorouracil cohort
averaged $509, compared to $296, $523, and $898 for the 1,
2–14, and >15 lesion cohorts, respectively. CONCLUSION: AK
is a common pre-malignant lesion that can develop into squa-
mous cell carcinoma. Numerous options are available for the
treatment of AK, all of which have been shown to be equally
efﬁcacious. In this study, use of 5% ﬂuorouracil cream for the
treatment of multiple AK lesions was cost saving compared to
cryosurgery. Similarly, because ﬂuorouracil is known to treat
sub-clinical lesions, additional savings may be realized for
periods longer than two years.
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The economic burden of psoriasis varies by disease severity.
Moderate to severe psoriasis requires use of systemic treatment
agents and is likely to be associated with higher medical costs.
OBJECTIVE: To estimate health care utilization rates and per-
patient costs for the treatment of moderate to severe psoriasis.
METHODS: A database of health insurance claims from 58 US
commercial health plans was used to obtain patient-level data.
Patients, aged 18–64, included in the analysis had a diagnosis of
psoriasis, and received >1 treatment cycle of at least one of the
following systemic agents: psoralen plus ultraviolet A (PUVA),
methotrexate (Mtx), cyclosporine, acitretin, etretinate, ultravio-
let B (UVB), and systemic corticosteroids (Cs). Patients with <6
months of observation period and those with rheumatoid arthri-
tis and other autoimmune diseases were excluded from the analy-
sis. RESULTS: A total of 1780 patients met all eligibility criteria
noted above (Group 1). Another 282 patients were newly diag-
nosed patients with no prior history of claims for psoriasis (New
Starts; Group 2). The most frequently used systemic therapies by
patients in Group 1, over a period of 1 year, were Cs (42%),
UVB (37%), PUVA (26%), and Mtx (22%). Of patients in
Group 2, 56%, 37%, 31%, and 18% received UVB, Cs, PUVA,
and Mtx. In an analysis of annual per-patient costs for drugs,
outpatient services, and inpatient services, results were compa-
rable for Groups 1 and 2. In Group 1, mean (median) annual
per-patient costs were $917 ($473), $199 ($85), and $6 ($0),
respectively and the corresponding costs for Group 2 were $744
($412), $179 ($63), and $0 ($0), respectively. 90th percentile
annual per-patient costs among all patients and New Starts were
$2932 and $2125, respectively. CONCLUSIONS: Estimates of
annual per-patient costs of treating moderate to severe psoriasis
exceed those reported previously, and reﬂect a considerable
direct medical burden.
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OBJECTIVE: To compare health care expenditures among
patients with dermatophytosis with different predisposing,
enabling and need factors as deﬁned by Andersen-Laake Behav-
ioral Model. METHODS: A cross-sectional analysis of the 1999
Medical Expenditure Panel Survey (MEPS) was conducted.
Patients with dermatophytosis aged 18 years and above were
included in the study. Health care expenditures included costs
related to prescription medications, outpatient, emergency room
and inpatient visits. Predisposing factors included age, gender,
race, education, and marital status. Enabling factors included
insurance type, employment status, family size and income. Need
factors included comorbid conditions, perceived mental and
health status. Analysis of covariance was used to compare the
levels of different factors affecting health care expenditures
adjusting for age. Sampling weights provided by MEPS were
used to provide representative estimates. RESULTS: A total of
156 patients with dermatophytosis were identiﬁed (ICD-9-CM
code = 110.x). These represented 1.8 million patients nationally.
The average age of patients was 51 years. The majority of the
respondents were female (52%); caucasian (87%) had private
insurance (80%) and was married (62%). Health care expendi-
tures for females was signiﬁcantly higher than for males ($831
vs. $450) (p = 0.03). Patients in families with less than three
members spent $232 more than those in families with three or
more members (p = 0.04). Patients with some college education
or higher had higher health care expenditures ($718) compared
with those who had attended high school ($581) or elementary
